Blockade of MK2 is protective in inflammation-associated colorectal cancer development

Anita L. Ray, Eliseo F. Castillo, Katherine T. Morris, Robert A. Nofchissey, Lea L. Weston, Von G. Samedi, Joshua A. Hanson, Matthias Gaestel, Iryna Pinchuk, Ellen J. Beswick

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Chronic inflammation is a risk factor for colorectal cancer. The MAPK-activated protein kinase 2 (MK2) pathway controls multiple cellular processes including p38-dependent inflammation. This is the first study to investigate the role of MK2 in development of colitis-associated colon cancer (CAC). Herein, we demonstrate that MK2-/- mice are highly resistant to neoplasm development when exposed to AOM/DSS, while wild type (WT) C57BL/6 develop multiple neoplasms with the same treatment. MK2-specific cytokines IL-1, IL-6 and TNF-α were substantially decreased in AOM/DSS treated MK2-/- mouse colon tissues compared with WT mice, which coincided with a marked decrease in macrophage influx. Restoring MK2-competent macrophages by injecting WT bone marrow derived macrophages into MK2-/- mice led to partial restoration of inflammatory cytokine production with AOM/DSS treatment; however, macrophages were not sufficient to induce neoplasm development. These results indicate that MK2 functions as an inflammatory regulator to promote colonic neoplasm development and may be a potential target for CAC. What's new? The role of inflammation in cancer development is intriguing, especially in colitis-associated colon cancer. Here the authors examine the role of MAP kinase-activated protein kinase 2 (MK2) in this process. They show that MK2-/- mice produce less cytokines (IL-1, IL-6 and TNF-alpha) and are highly resistant to cancer development, a process only partially reversed by transfusion of wildtype macrophages. The data identify MK2 as an inflammatory regulator in colon cancer development and a possible new drug target for this disease.

Original languageEnglish (US)
Pages (from-to)770-775
Number of pages6
JournalInternational Journal of Cancer
Volume138
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

Protein Kinases
Colorectal Neoplasms
Inflammation
Colonic Neoplasms
Macrophages
Neoplasms
Colitis
Cytokines
Interleukin-1
Interleukin-6
Colon
Tumor Necrosis Factor-alpha

Keywords

  • Colorectal Cancer
  • IL-1
  • IL-6
  • macrophages
  • MK2
  • TNF-α

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ray, A. L., Castillo, E. F., Morris, K. T., Nofchissey, R. A., Weston, L. L., Samedi, V. G., ... Beswick, E. J. (2016). Blockade of MK2 is protective in inflammation-associated colorectal cancer development. International Journal of Cancer, 138(3), 770-775. https://doi.org/10.1002/ijc.29716

Blockade of MK2 is protective in inflammation-associated colorectal cancer development. / Ray, Anita L.; Castillo, Eliseo F.; Morris, Katherine T.; Nofchissey, Robert A.; Weston, Lea L.; Samedi, Von G.; Hanson, Joshua A.; Gaestel, Matthias; Pinchuk, Iryna; Beswick, Ellen J.

In: International Journal of Cancer, Vol. 138, No. 3, 01.02.2016, p. 770-775.

Research output: Contribution to journalArticle

Ray, AL, Castillo, EF, Morris, KT, Nofchissey, RA, Weston, LL, Samedi, VG, Hanson, JA, Gaestel, M, Pinchuk, I & Beswick, EJ 2016, 'Blockade of MK2 is protective in inflammation-associated colorectal cancer development', International Journal of Cancer, vol. 138, no. 3, pp. 770-775. https://doi.org/10.1002/ijc.29716
Ray AL, Castillo EF, Morris KT, Nofchissey RA, Weston LL, Samedi VG et al. Blockade of MK2 is protective in inflammation-associated colorectal cancer development. International Journal of Cancer. 2016 Feb 1;138(3):770-775. https://doi.org/10.1002/ijc.29716
Ray, Anita L. ; Castillo, Eliseo F. ; Morris, Katherine T. ; Nofchissey, Robert A. ; Weston, Lea L. ; Samedi, Von G. ; Hanson, Joshua A. ; Gaestel, Matthias ; Pinchuk, Iryna ; Beswick, Ellen J. / Blockade of MK2 is protective in inflammation-associated colorectal cancer development. In: International Journal of Cancer. 2016 ; Vol. 138, No. 3. pp. 770-775.
@article{ddad134527334d3e9493d53b9795755b,
title = "Blockade of MK2 is protective in inflammation-associated colorectal cancer development",
abstract = "Chronic inflammation is a risk factor for colorectal cancer. The MAPK-activated protein kinase 2 (MK2) pathway controls multiple cellular processes including p38-dependent inflammation. This is the first study to investigate the role of MK2 in development of colitis-associated colon cancer (CAC). Herein, we demonstrate that MK2-/- mice are highly resistant to neoplasm development when exposed to AOM/DSS, while wild type (WT) C57BL/6 develop multiple neoplasms with the same treatment. MK2-specific cytokines IL-1, IL-6 and TNF-α were substantially decreased in AOM/DSS treated MK2-/- mouse colon tissues compared with WT mice, which coincided with a marked decrease in macrophage influx. Restoring MK2-competent macrophages by injecting WT bone marrow derived macrophages into MK2-/- mice led to partial restoration of inflammatory cytokine production with AOM/DSS treatment; however, macrophages were not sufficient to induce neoplasm development. These results indicate that MK2 functions as an inflammatory regulator to promote colonic neoplasm development and may be a potential target for CAC. What's new? The role of inflammation in cancer development is intriguing, especially in colitis-associated colon cancer. Here the authors examine the role of MAP kinase-activated protein kinase 2 (MK2) in this process. They show that MK2-/- mice produce less cytokines (IL-1, IL-6 and TNF-alpha) and are highly resistant to cancer development, a process only partially reversed by transfusion of wildtype macrophages. The data identify MK2 as an inflammatory regulator in colon cancer development and a possible new drug target for this disease.",
keywords = "Colorectal Cancer, IL-1, IL-6, macrophages, MK2, TNF-α",
author = "Ray, {Anita L.} and Castillo, {Eliseo F.} and Morris, {Katherine T.} and Nofchissey, {Robert A.} and Weston, {Lea L.} and Samedi, {Von G.} and Hanson, {Joshua A.} and Matthias Gaestel and Iryna Pinchuk and Beswick, {Ellen J.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1002/ijc.29716",
language = "English (US)",
volume = "138",
pages = "770--775",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Blockade of MK2 is protective in inflammation-associated colorectal cancer development

AU - Ray, Anita L.

AU - Castillo, Eliseo F.

AU - Morris, Katherine T.

AU - Nofchissey, Robert A.

AU - Weston, Lea L.

AU - Samedi, Von G.

AU - Hanson, Joshua A.

AU - Gaestel, Matthias

AU - Pinchuk, Iryna

AU - Beswick, Ellen J.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Chronic inflammation is a risk factor for colorectal cancer. The MAPK-activated protein kinase 2 (MK2) pathway controls multiple cellular processes including p38-dependent inflammation. This is the first study to investigate the role of MK2 in development of colitis-associated colon cancer (CAC). Herein, we demonstrate that MK2-/- mice are highly resistant to neoplasm development when exposed to AOM/DSS, while wild type (WT) C57BL/6 develop multiple neoplasms with the same treatment. MK2-specific cytokines IL-1, IL-6 and TNF-α were substantially decreased in AOM/DSS treated MK2-/- mouse colon tissues compared with WT mice, which coincided with a marked decrease in macrophage influx. Restoring MK2-competent macrophages by injecting WT bone marrow derived macrophages into MK2-/- mice led to partial restoration of inflammatory cytokine production with AOM/DSS treatment; however, macrophages were not sufficient to induce neoplasm development. These results indicate that MK2 functions as an inflammatory regulator to promote colonic neoplasm development and may be a potential target for CAC. What's new? The role of inflammation in cancer development is intriguing, especially in colitis-associated colon cancer. Here the authors examine the role of MAP kinase-activated protein kinase 2 (MK2) in this process. They show that MK2-/- mice produce less cytokines (IL-1, IL-6 and TNF-alpha) and are highly resistant to cancer development, a process only partially reversed by transfusion of wildtype macrophages. The data identify MK2 as an inflammatory regulator in colon cancer development and a possible new drug target for this disease.

AB - Chronic inflammation is a risk factor for colorectal cancer. The MAPK-activated protein kinase 2 (MK2) pathway controls multiple cellular processes including p38-dependent inflammation. This is the first study to investigate the role of MK2 in development of colitis-associated colon cancer (CAC). Herein, we demonstrate that MK2-/- mice are highly resistant to neoplasm development when exposed to AOM/DSS, while wild type (WT) C57BL/6 develop multiple neoplasms with the same treatment. MK2-specific cytokines IL-1, IL-6 and TNF-α were substantially decreased in AOM/DSS treated MK2-/- mouse colon tissues compared with WT mice, which coincided with a marked decrease in macrophage influx. Restoring MK2-competent macrophages by injecting WT bone marrow derived macrophages into MK2-/- mice led to partial restoration of inflammatory cytokine production with AOM/DSS treatment; however, macrophages were not sufficient to induce neoplasm development. These results indicate that MK2 functions as an inflammatory regulator to promote colonic neoplasm development and may be a potential target for CAC. What's new? The role of inflammation in cancer development is intriguing, especially in colitis-associated colon cancer. Here the authors examine the role of MAP kinase-activated protein kinase 2 (MK2) in this process. They show that MK2-/- mice produce less cytokines (IL-1, IL-6 and TNF-alpha) and are highly resistant to cancer development, a process only partially reversed by transfusion of wildtype macrophages. The data identify MK2 as an inflammatory regulator in colon cancer development and a possible new drug target for this disease.

KW - Colorectal Cancer

KW - IL-1

KW - IL-6

KW - macrophages

KW - MK2

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=84955641903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955641903&partnerID=8YFLogxK

U2 - 10.1002/ijc.29716

DO - 10.1002/ijc.29716

M3 - Article

C2 - 26238259

AN - SCOPUS:84955641903

VL - 138

SP - 770

EP - 775

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -